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Edited by Veli-Pekka LehtoAbstract The present report provides evidence that, in A431
cells, interferon c (IFNc) induces the rapid (within 5 min), and
reversible, tyrosine phosphorylation of the epidermal growth
factor receptor (EGFR). IFNc-induced EGFR transactivation
requires EGFR kinase activity, as well as activity of the
Src-family tyrosine kinases and JAK2. Here, we show that
IFNc-induced STAT1 activation in A431 and HeLa cells
partially depends on the kinase activity of both EGFR and
Src. Furthermore, in these cells, EGFR kinase activity is essen-
tial for IFNc-induced ERK1,2 activation. This study is the ﬁrst
to demonstrate that EGFR is implicated in IFNc-dependent
signaling pathways.
 2007 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
Keywords: IFNc; Transactivation; Epidermal growth factor
receptor; STAT1; Tyrosine phosphorylation1. Introduction
The cell surface receptor for the epidermal growth factor
(EGF) is a 170-kDa glycoprotein which possesses an intrinsic
tyrosine kinase activity. Several structurally related proteins,
including EGF, transforming growth factor-a (TGF-a) and
heparin-binding EGF (HB-EGF), are recognized as direct ago-
nists. Binding of each of these growth factors to the EGF
receptor (EGFR) promotes its activation through a mecha-
nism that involves dimerization, activation of the receptor
tyrosine kinase domain and autophosphorylation of the recep-
tor. The binding of phosphorylated EGFR tyrosines to down-
stream signaling proteins initiates multiple signaling cascades,
including Ras-MAPK (mitogen-activated protein kinase) –
and STAT (signal transducer and activator of transcription)
– pathways that culminate in cell proliferation, apoptosis or
diﬀerentiation [1].Abbreviations: EGF, epidermal growth factor; EGFR, epidermal
growth factor receptor; IFNc, interferon gamma; IFNcR, interferon
gamma receptor; JAK, Janus kinase; STAT, signal transducer and
activator of transcription; TGF-a, transforming growth factor-a; HB-
EGF, heparin-binding EGF like growth factor; GPCR, G-protein
coupled receptor; MAPK, mitogen-activated protein kinase; ERK,
extracellular signal-regulated kinase; ADAM, a disintegrin and metal-
loprotease; GH, growth hormone; IL, interleukine; Pyk2, proline-rich
tyrosine kinase 2
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doi:10.1016/j.febslet.2007.03.002The activation of EGFR pathways is not limited to direct
agonists, but can occur by cross-talk with other signaling path-
ways. An increasing number of studies reports a rapid phos-
phorylation of EGFR on tyrosine upon stimulation of cells
with a variety of G-protein coupled receptor (GPCR) agonists,
cytokines, as well as in response to integrin-mediated adhesion
and environmental stressors (reviewed in [2]). The molecular
mechanisms for the EGFR signal transactivation in response
to these factors vary with the cell type and stimuli. Generally,
several cytoplasmic signaling proteins such as tyrosine kinases
Src and proline-rich tyrosine kinase 2 (Pyk2), as well as protein
kinase C have been implicated in the transactivation process.
Moreover, in diﬀerent cellular systems the intracellular
Ca2+concentration and generation of reactive oxygen species
were shown to be critical for EGFR signal transactivation. Re-
cent investigations have demonstrated that the mechanisms of
EGFR transactivation by GPCR agonists involve processing
of transmembrane growth factor precursors by metallopro-
teases of the ADAM (a disintegrin and metalloprotease) family
of zinc-dependent proteases (reviewed in [3]). Presently, the
ectodomain shedding of EGFR ligands is emerged as a critical
component in the functional activation of EGFR in the inter-
receptor cross-talk. Collectively, EGFR transactivation has
been shown to be employed in a wide array of biological sig-
naling processes. In this regard, EGFR transactivation is a
current topic of signal transduction research.
Interferon gamma (IFNc) is a potent immunomodulatory
cytokine that exerts its pleiotropic biological eﬀects by inter-
acting with its cognate cell surface receptor (IFNcR) [4]. Liga-
tion of IFNcR that lacks kinase catalytic domain initiates
intracellular signaling, in which STAT1 is one of the most
important players. Receptor-associated tyrosine kinases
JAK1/JAK2 activate via tyrosine phosphorylation STAT1,
which subsequently forms a homodimer, translocates to the
nucleus and initiates transcription of IFNc inducible genes (re-
viewed in [5]). Although the mechanisms and mediators in-
volved in JAK–STAT signaling are well known [4,5], the
possibility that others receptor systems, in particular EGFR,
also operate in the regulation of IFNc-dependent downstream
signaling pathways has not been investigated thus far. There is
only one report [6] which describes IFNc-induced EGFR acti-
vation. However, in that study, the eﬀect of IFNc was ob-
served only 24 h after stimulation and linked to the elevated
intracellular level of the TGF-a.
The aim of the present study was to examine the possibility
of EGFR transactivation in response to IFNc in the human
epidermoid carcinoma cells, and to explore a role for the recep-
tor in the regulation of IFNc signaling. Our ﬁndings indicate
that signal generated by IFNc can modulate EGFR activityblished by Elsevier B.V. All rights reserved.
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signaling pathways.2. Materials and methods
All reagents except specially marked were from Sigma. Murine EGF
was puriﬁed as described previously [7].
2.1. Cell cultures and cell treatment
A431, HeLa and HEK293 cells, obtained from European Collection
of Cell Cultures, were cultivated in DMEM (Paneco, Russia) supple-
mented with 10% fetal calf serum (PAA Laboratories, Austria) and
80 lg/ml gentamycin (KRKA, Slovenia). The cells were seeded in 60-
mm dishes (Nunc) and, at 70–80% conﬂuency, were serum starved
for 16–20 h before experiments. The cells were stimulated with 10 ng/
ml hrIFNc (Sigma) or 100 ng/ml mEGF or, when indicated, pretreated
with diﬀerent inhibitors: 5 lM AG1478 (Sigma), 50 lM AG490 (Sig-
ma), 1 lM CGP77675 (Novartis) for 60 min at 37 C and then stimu-
lated.
The data on the relative expression of EGFR and IFNcR in the
cell lines tested (the number of expressed EGF and IFNc mem-
brane receptors per cell, respectively): A431 human epidermoid
carcinoma cells: 2.6 · 106 and 2.7 · 104; HEK293 human embryonic
kidney cells: less 1 · 104 and a few hundred; HeLa cells: 4.7 · 104
and 4.2 · 103.
2.2. Antibodies
Monoclonal antibody against phosphotyrosine (clone PY-20) was
from Sigma. Monoclonal antibodies against EGFR (clone 4F10) and
STAT1, as well as polyclonal antibodies against pY701 STAT1,
pT202/pY204 ERK1,2 and EGFR C-terminal phosphotyrosines 845,
992, 1045, 1068, 1148, 1173 were from Cell Signaling Technology.
Polyclonal antibody against ERK1,2 was from Santa Cruz Biotechnol-
ogy. Secondary anti-mouse and anti-rabbit HRP-conjugated antibod-
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Fig. 1. IFNc induces EGFR tyrosine phosphorylation in A431 cells. (A,B)
indicated times, and the cell proteins were analyzed by Western blot analy
antibody. (B) Proteins of cell lysates were immunoprecipitated with anti-
phosphotyrosine antibody (top panel) or with anti-EGFR antibody (bottom
for 1 min or pretreated with indicated inhibitors for 60 min before IFNc
antibody. (D) Total lysates from A431 cells untreated or stimulated with IFN
C-terminal phosphotyrosines. C – untreated total cell lysates.2.3. Immunoprecipitation and Western blotting
To prepare total lysates, the cells were washed twice with ice-cold
PBS and lyzed on ice in lysis buﬀer [50 mM Tris–HCl (pH 7.4), 1% Tri-
ton X-100, 10% glycerol, 150 mM NaCl, 1 mM EDTA, 1 mM NaF, 1
mM Na3VO4, 1 mM PMSF and protease inhibitors cocktail (Sigma,
P8340, dilution 1:300)] for 10 min. The lysate was clariﬁed by centrifu-
gation at 15000 · g for 15 min. Protein content was determined by the
method of Bradford. For immunoprecipitation, 500 lg of cellular pro-
teins was incubated with 1 lg of anti-EGFR antibody at 4 C over-
night and then 25 ll of 25% slurry of protein G-agarose beads was
added. The beads were incubated at 4 C for 1 h and subsequently
washed with ice-cold lysis buﬀer. The cell lysates and immunoprecipi-
tation probes were mixed with 5· Laemmli sample buﬀer (50 mM Tris–
HCl, pH 6.8, 2% SDS, 10% glycerol, 1% b-mercaptoethanol, 0,02%
bromophenol blue ﬁnal concentrations) and boiled for 5 min. Samples
containing equal amounts of protein (100 lg) were analyzed by SDS–
PAGE (8% gel) and transferred to nitrocellulose membrane (Bio-Rad)
according to standard manufacture protocols (Bio-Rad Laboratories).
Proteins were detected with Western procedure according to antibody
manufacture instruction and visualized by ECL method with Hyper-
ﬁlm (CEA) (Amersham Biosciences). Representative results of the
three experiments are shown in ﬁgures.3. Results
3.1. IFNc transactivates EGFR in A431 cells
To test the hypothesis that IFNc induces the transactivation
of EGFR, we performed time course experiments of EGFR
phosphorylation in IFNc-treated A431 cells overexpressing
EGFR. It is known that EGF stimulates a rapid and continued
phosphorylation of EGFR in A431 cells [8]. By contrast, hu-
man IFNc caused a rapid and reversible tyrosine phosphoryla-
tion of EGFR, peaking at 1–5 min and returning progressively
to the baseline by 15 min (Fig. 1A). ImmunoprecipitationpY1173
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Cells were stimulated with 10 ng/ml IFNc or 100 ng/ml EGF for the
sis. (A) Total lysates were immunoblotted with anti-phosphotyrosine
EGFR antibody. The immunoprecipitates were analyzed with anti-
panel). (C) Cells were stimulated with both EGF for 10 min and IFNc
stimulation. Total lysates were analyzed with anti-phosphotyrosine
c for 1 min were immunoblotted with speciﬁc antibodies against EGFR
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EGFR (Fig. 1B). IFNc altered tyrosine phosphorylation with-
out aﬀecting steady-state protein levels of EGFR (Fig. 1B).
The current study is the ﬁrst to present evidence of the rapid
and transient transactivation of EGFR in response to IFNc.
3.2. IFNc-induced EGFR phosphorylation requires tyrosine
kinase activity of EGFR
EGF binding to EGFR is known to initiate an intrinsic tyro-
sine kinase activity resulting in autophosphorylation of the
receptor. To examine if IFNc-induced EGFR phosphorylation
requires the kinase activity of the receptor, we employed
speciﬁc EGFR tyrosine kinase inhibitor, tyrphostin AG1478.
Pretreatment of A431 cells with AG1478 abolished IFNc-stim-
ulated EGFR tyrosine phosphorylation (Fig. 1C). These ﬁnd-
ings clearly demonstrate that EGFR phosphorylation initiated
by IFNc requires its an intrinsic kinase activity.
To characterize the IFNc-dependent tyrosine phosphoryla-
tion of EGFR further, we analyzed phosphorylation of the spe-
ciﬁc sites within the cytoplasmic domain of EGFR. Among the
C-tail tyrosine residues, Tyr992, Tyr1045, Tyr1068, Tyr1086,
Tyr1148 and Tyr1173 have been considered previously as auto-
phosphorylation sites [9]. EGFR may be also phosphorylated
on Tyr845 that resides in the receptor kinase domain [10].We ob-
served signiﬁcant EGFR autophosphorylation in response to
IFNc in A431 cells (Fig. 1D). Tyr845, Tyr992, Tyr1045, Tyr1068
and Tyr1148 all were phosphorylated 1 min following IFNc
stimulation, however, the degree of their phosphorylation was
diﬀerent. These data indicate that IFNc, like EGF, induces
EGFR tyrosine phosphorylation via an autophosphorylation
mechanism. Importantly, of ﬁve autophosphorylation sites
tested, there is no increase of Tyr1173 phosphorylation in
IFNc-treated cells as compared with the control cells.
3.3. Inhibitors of Src kinases and JAK2 suppress the induction of
EGFR activation by IFNc
It was reported that Src kinases cooperate with the EGFR in
several signaling settings [11] and are involved in signal trans-0   2 5 15 30    15    15  (min)
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Fig. 2. IFNc-induced STAT1 tyrosine phosphorylation in various cells. (A–C
for the indicated times or pretreated with the inhibitors of EGFR kinase (AG
lysates were analyzed with anti-phosphotyrosine STAT1 antibody (top paneduction events initiated by IFNc [12]. We examined whether
EGFR activation by IFNc can occur by Src kinase-dependent
mechanism. Exposure of A431 cells to CGP77675, a speciﬁc
inhibitor of Src-family tyrosine kinases [13], strongly reduced
IFNc-induced EGFR phosphorylation (Fig. 1C), suggesting
that activity of Src kinases is required for the EGFR transac-
tivation. Further, we explored whether JAK2 tyrosine kinase is
involved in this process. Surprisingly, preincubation of A431
cells with AG490, a speciﬁc inhibitor of JAK2 kinase [14],
markedly reduced IFNc-stimulated phosphorylation of EGFR
(Fig. 1C). Taken together, our ﬁndings suggest that Src-family
kinases and JAK2 kinase are implicated in IFNc-mediated
transactivation of EGFR, suggesting the new role of JAK2
as a mediator of the transactivation of EGFR.
3.4. Involvement of EGFR transactivation in IFNc-induced
STAT1 activation
To explore a role for EGFR in the regulation of IFNc sig-
naling, we hypothesized that the contribution of the transacti-
vated EGFR in the IFNc-initiated activation of the
downstream signaling proteins STAT1 and ERK1,2 may de-
pend on the EGFR quantity on plasma membrane, as well
as the ratio of EGFR and IFNcR in cells.
To test the activation of STAT1, a major IFNcR down-
stream signal protein, we compared the time course of the
IFNc-induced STAT1 activation in A431, HeLa and
HEK293 cells, which express a diﬀerent amount of both recep-
tors. In both A431 and HEK293 cells, IFNc stimulation in-
duced a strong activation of STAT1, peaking at 15 to 30 min
(Fig. 2A,C). A similar pattern of STAT1 phosphorylation
was detected also in HeLa cells. To ascertain the involvement
of EGFR in the regulation of STAT1 activation, we studied
the eﬀect of AG1478 on STAT1 tyrosine phosphorylation by
IFNc. Remarkably, the inhibitor reduced, but did not abro-
gate, STAT1 phosphorylation following IFNc treatment of
both A431 (Fig. 2A) and HeLa cells (Fig. 2B). This decrease
was most pronounced in A431 cells. Consequently, IFNc-in-
duced STAT1 activation, at least in part, could depend on-STAT1 →
HeLa
pY-STAT1←
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) A431, HeLa and HEK293 cells were stimulated with 10 ng/ml IFNc
1478) or Src kinases (CGP77675) for 60 min before stimulation. Total
l) or anti-STAT1 antibody (bottom panel).
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no eﬀect on IFNc-induced STAT1 phosphorylation in
HEK293 cells (Fig. 2C). Together these ﬁndings indicate that,
in cells expressing high levels of EGFR, IFNc-stimulated
STAT1 activation is mediated not only by IFNcR, but, in
addition, by transactivated EGFR. The current study is the
ﬁrst to present evidence of the involvement of EGFR in
IFNc-induced STAT1 activation.
3.5. Src-family kinases mediate IFNc-induced STAT1 activation
To explore the role of Src-family kinases in the regulation of
IFNc-induced STAT1 activation, we analyzed the level of
STAT1 tyrosine phosphorylation in A431 and HEK293 cells
pretreated with CGP77675. Exposure of cells to CGP77675 re-
duced IFNc-initiated STAT1 phosphorylation (Fig. 2A,C).
These results suggest that Src kinases can mediate IFNc-in-
duced STAT1 activation.
3.6. Intrinsic EGFR tyrosine kinase is critical for IFNc-induced
ERK 1,2 activation
In addition to the JAK/STAT signaling pathway, IFNc has
been reported to activate MAP kinases ERK1,2 cascade in sev-
eral cell types [15–17]. Next, we assessed the activation of
MAP kinases ERK1,2 in response to IFNc in A431, HeLa
and HEK293 cells. We found that, in all tested cells, IFNc
stimulation produced a marked increase in the phosphoryla-
tion of ERK1,2, peaking at 15 min. To elucidate whether the
EGFR kinase activity is necessary for IFNc-induced activation
of ERK1,2, we tested the eﬀect of AG1478 on ERK1,2 activa-
tion in these cells. In A431 cells, AG1478 abrogated IFNc-in-
duced phosphorylation of ERK1,2, whereas in HeLa the
inhibitor strongly diminished ERK1,2 phosphorylation
(Fig. 3), suggesting that EGFR tyrosine kinase is responsible
for ERK1,2 activation in A431 and HeLa cells. By contrast,
ERK1,2 phosphorylation was unaﬀected by AG1478 in
HEK293 cells (Fig. 3), suggesting that EGFR tyrosine kinase
is not involved in IFNc-induced ERK1,2 activation. From
these ﬁndings we propose that, in A431 and HeLa cells, trans-
activated EGFR wholly mediates ERK1,2 activation in re-
sponse to IFNc, whereas in HEK293 cells, in which EGFR
transactivation is impossible (or not detectable), ERK1,2 acti-
vation is provided directly through IFNcR.
Thus, we can conclude that IFNc-dependent EGFR transac-
tivation and its contribution to signaling correlate with EGFR
quantity on cell surface as well as with EGFR/IFNcR ratio.A431 HEK293 HeLa
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Fig. 3. Eﬀect of EGFR tyrosine kinase inhibitor on IFNc-induced
activation of ERK1,2. A431, HEK293 and HeLa cells were stimulated
with 10 ng/ml IFNc for 15 min or pretreated with AG1478 for 60 min
before stimulation. Total lysates were immunoblotted with anti-pT202/
pY204 ERK1,2 antibody (top panel) or anti-ERK1,2 antibody
(bottom panel). C – untreated total cell lysates.4. Discussion
Understanding of the interplay between various signal trans-
duction pathways in cells has been of intense interest over the
past few years. Transactivation of the EGFR has previously
been demonstrated to be a key event in signaling emanating
from a variety of GPCRs, adhesion receptors, and some cyto-
kine receptors. However, the possibility that EGFR can also
operate in the regulation of IFNc-dependent signaling path-
ways remains unexplored.
In the present report, we provide evidence of EGFR transac-
tivation in IFNc-treated A431 cells overexpressing EGFR. In
contrast to the usual prolonged and continued EGFR activa-
tion in response to EGF, IFNc-induced EGFR activation
occurs within minutes of the stimulation. The pattern of
IFNc-induced EGFR activation is similar to the rapid and
reversible EGFR activation by H2O2, UV and alkylating
agents [18,19]. Here, we show that several EGFR tyrosine res-
idues become phosphorylated in response to IFNc: Tyr845,
Tyr992, Tyr1045, Tyr1068 and Tyr1148, excluding Tyr1173, a major
autophosphorylation site in response to EGF.
In order to clarify the mechanism of IFNc-induced EGFR
transactivation in A431 cells, we utilized an inhibitor analysis
of the phosphorylation status of EGFR. IFNc-induced EGFR
tyrosine phosphorylation is completely blocked by pharmaco-
logical inhibition of the intrinsic EGFR tyrosine kinase
strongly suggesting that increased EGFR kinase activity con-
trols the phosphorylation process. Similarly, our previous
studies demonstrated that both H2O2- and oxidized glutathi-
one-dependent EGFR transactivation in A431 cells requires
an active EGFR tyrosine kinase [20,21]. Furthermore, EGFR
transactivation by various GPCRs was reported to be depen-
dent on an intact EGFR kinase [2].
Further, we tested the role of the non-receptor tyrosine ki-
nases of Src-family as the most prominent mediators of EGFR
transactivation. The inhibition of the cellular Src kinases activ-
ity signiﬁcantly diminished EGFR tyrosine phosphorylation
by IFNc, implicating Src kinases in the regulation of the recep-
tor transactivation. We propose that Src kinases can regulate
IFNc-induced EGFR kinase activity through Tyr845 phos-
phorylation. As shown earlier, c-Src is responsible for the
EGF-induced EGFR phosphorylation on Tyr845, which results
in hyperactivation of receptor kinase [10]. Another non-recep-
tor tyrosine kinase JAK2 is known to be critical in the regula-
tion of IFNcR function [4,5]. The results presented in our
study allow speculation of JAK2 involvement in IFNc-induced
EGFR transactivation. Previously, JAK2-dependent EGFR
phosphorylation on Tyr1068 in response to growth hormone
(GH) has been demonstrated [22]. However, this process did
not depend on EGFR tyrosine kinase. Thus, in A431 cells,
IFNc-induced transactivation of EGFR was mediated partly
via JAK2 and Src kinases and required EGFR kinase activa-
tion.
Recent studies have identiﬁed ADAMs as a key metallopro-
teases activated by GPCR agonists to produce a mature
EGFR ligand leading to EGFR transactivation [3]. In contrast
to well-documented ADAM-dependent EGFR transactivation
by GPCRs, the detailed mechanisms of EGFR transactivation
via ADAMs in response to the cytokines are still unknown.
Among the cytokines, which induce EGFR transactivation,
only GH and IL-6 have been described so far. Although sev-
eral reports demonstrated that an inducible cleavage of the
E. Burova et al. / FEBS Letters 581 (2007) 1475–1480 1479GH receptor catalyzed by ADAM17 can be inhibited by GH
[23], this eﬀect does not appear to be related to EGFR trans-
activation in response to GH. It was recently shown that the
cytokine IL-4 stimulation can activate ADAM8 [24]. However,
there is no information available as to whether IL-4 induces
the EGFR transactivation. At present, little is known about
how ADAMs are regulated and how they are involved in the
EGFR transactivation by cytokines. Nevertheless, we can
not exclude that IFNc induces EGFR transactivation through
metalloprotease-dependent shedding of EGFR ligands. This
possibility is supported by data presented in the current study
that IFNc induces EGFR tyrosine phosphorylation via auto-
phosphorylation mechanism. Future investigations will have
to focus on the elucidation of the precise mechanism of EGFR
transactivation via ADAMs stimulation in response to IFNc.
To explore a possible role for the transactivated EGFR in
the regulation of IFNc signaling pathways, we tested the acti-
vation of STAT1 and ERK1,2, which represent the points of
convergence for signals generating from both IFNc and
EGF [25]. Presently, IFNc is generally accepted to activate
STAT1 via its own receptor. The most signiﬁcant ﬁnding re-
ported in the present study is that IFNc utilizes an additional
signaling mechanism through Src/JAK2-dependent EGFR
transactivation to stimulate STAT1 activation. It is notewor-
thy that the additional mechanism depends on the cell type
and EGFR expression. Indeed, inhibition of EGFR tyrosine
kinase by AG1478 results in the profound decrease in IFNc-
stimulated STAT1 phosphorylation in A431 and HeLa cells,
that express high levels of EGFR, but not in HEK293 cells,
that express low levels of EGFR. It is of note that, in A431
cells, IFNc-induced increase in STAT1 phosphorylation corre-
lates with the phosphorylation of Tyr1148. This site is known
preferentially to provide the interaction EGFR and STAT1
in response to EGF [9]. We assume that phosphorylated
Tyr1148 can be an important mediator of IFNc-stimulated
STAT1 activation. In addition we conclude that STAT1 acti-
vation can occur by a Src kinase-dependent mechanism. Src ki-
nase activity is known to mediate EGF-induced activation of
STATs [26]. Moreover, it was shown recently that Src-depen-
dent phosphorylation of EGFR Tyr845 plays a critical role in
STAT activation in response to both EGF and H2O2 in
A431cells [27]. At this stage, we can not exclude the possibility
that Src-kinases are implicated in IFNc-induced STAT1 acti-
vation via EGFR phosphorylation on Tyr845.
Another important ﬁnding of our study is that, depending
on the cell type, EGFR kinase activity is essential for IFNc-in-
duced ERK1,2 activation. Surprisingly, we found that EGFR
tyrosine kinase is responsible for any ERK1,2 activation in
IFNc-treated A431 and HeLa cells. By contrast, in HEK293
cells, IFNc-induced activation of ERK1,2 did not depend on
the activity of EGFR tyrosine kinase. It was postulated that
c-Src and EGFR act synergistically (via phosphorylation of
the receptor by c-Src) to induce enhanced signaling in cells
overexpressing both these kinases [10]. It is not surprising
therefore, that IFNc-dependent activation of signaling path-
ways, resulting from high levels of EGFR and Src in A431
and HeLa cells, could be quite diﬀerent from those that are
mediated by low levels of these kinases in HEK293 cells. Col-
lectively, our data indicate that EGFR is an important compo-
nent of the signaling pathways initiated by IFNc suggesting
cross-talk between IFNcR and EGFR.IFNc exerts cytostatic and immunomodulatory eﬀects on
carcinoma cells, in which overexpression of EGFR is a poor
prognostic indicator. IFNc has been demonstrated to inhibit
the growth of tumors in vivo and the proliferation of many
transformed cell types in vitro, including A431 [28] and HeLa
cells [29]. The molecular mechanism underlying an anti-prolif-
erative eﬀect of IFNc is known to involve STAT1 activation,
resulting in apoptosis [30]. In addition, IFNc-induced growth
inhibition was shown to be accompanied with the enhanced
expression of EGFR in A431 cells [28,31], that can be ex-
plained by the EGFR transactivation in response to IFNc.
We suspect that, in cells expressing high levels of EGFR, an
anti-proliferative eﬀect of IFNc is associated with the involve-
ment of EGFR transactivation in IFNc signaling at the level of
STAT1 activation, suggesting a role for EGFR as a mediator
between IFNcR and IFNc-inducible genes. Moreover, EGFR
is crucial also for the IFNc eﬀect on the MAP kinases signal
transduction pathway, implicating in the regulation of the
ERK1,2 activity. In summary, IFNc-stimulated EGFR trans-
activation has an important functional signiﬁcance. We postu-
late that physiological eﬀect of IFNc on epidermoid cancer
cells via STAT1 and MAP kinases signal transduction path-
ways is provided partly or fully by EGFR transactivation,
resulting in the regulation of the cell growth and/or gene
expression in cells. This may have clinical implications for
improving combined treatment of the various carcinoma cells
based on targeting of IFNcR and EGFR.
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